A Multicenter, Randomized, Double-Blind, Parallel Group, Controlled, 16 week Study to Evaluate the Efficacy and Safety of a Digital Therapeutic (CT155) as an Adjunct to Standard of Care Antipsychotic Therapy in Adult and Late Adolescent Participants
with Experiential Negative Symptoms of Schizophrenia
Criteria:Must be 18 yrs of age
Confirmed diagnosis of Schizophrenia
Fluent in written and spoken English, confirmed by ability to read and understand the informed consent form.
Is on a stable dose of antipsychotic medication(s) for at least 12 weeks prior to the study.
Is not taking more than 2 anti pysychotic medications